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Abstract
Background: Observational data suggest that serum magnesium (Mg) concentration is inversely related to vascular
calcification and hyperparathyroidism among patients with end-stage renal disease (ESRD). In recent years, there have
been several case reports of hypomagnesemia due to use of proton-pump inhibitors (PPI), with the hypomagnesemia
attributed to inappropriate gastrointestinal (GI) Mg loss. We hypothesized that the tendency to GI Mg loss is more
common than is currently reported. Since patients with ESRD have little to no renal Mg loss to affect serum Mg
concentration, dialysis patients are an interesting population in whom to study the relationship between PPI use and
serum Mg levels.
Methods: Using a single-center cross-sectional design, we studied 155 prevalent hemodialysis (HD) patients. Serum Mg
concentration for each patient was determined based on the mean of 3 consecutive serum Mg levels drawn at 6 week
intervals. PPI use at the time of the blood tests was documented. The relationship between PPI use and Mg concentration
was determined in unadjusted analyses, as well as after adjustment for age, gender, race, cause of ESRD, diabetes, time on
HD and dialysate Mg concentration.
Results: 55 % of patients were on PPIs at the time of the study. The majority of patients (62 %) used a dialysate Mg
(in mmol/L) of 0.5, and the remainder (38 %) used a dialysate Mg of 0.375. Serum Mg levels were significantly lower
among PPI users vs. non-users (0.93 vs. 1.02 mmol/L, p < 0.001). This finding persisted after stratifying for dialysate Mg
concentration, and after multivariable adjustment (p < 0.001). In addition, more PPI users vs. non-users had a Mg
level < 1 mmol/L (79 % vs. 43 %) and a Mg level < 0.8 mmol/L (16 % vs. 4 %). There was a non-significant trend toward
increased time on PPI being associated with lower serum Mg levels (p = 0.067).
Conclusion: Among HD patients, PPI users have lower serum Mg levels as compared with non-users. Further research is
required to determine whether the magnitude of change in Mg levels among PPI users is associated with adverse
outcomes.
Background
In recent years, there have been several case reports of
hypomagnesemia due to proton-pump inhibitor (PPI) use
[1–6]. In each of these cases, the hypomagnesemia was
identified because it was severe enough to cause symptoms.
As a result of these reports, in 2011, the Food and Drug
Administration in the Unites States sent out a Drug Safety
Communication warning that low magnesium (Mg) levels
may be associated with long-term use of PPIs. In these case
reports of PPI-induced hypomagnesemia, renal excretion of
Mg was appropriately low, suggesting that the etiology is
related to GI loss of Mg through a mechanism that has not
yet been fully elucidated. While this may be an idiosyncratic
reaction, it is plausible that the high gastric pH present in
PPI users may alter Mg transport resulting in a tendency to
GI Mg loss in all patients using PPIs. If this is the case, the
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development and severity of hypomagnesemia would de-
pend on a combination of the extent of GI Mg loss and Mg
intake.
Some observational data have started to emerge link-
ing PPIs with hypomagnesemia [7–10], although the
data are conflicting [11, 12]. Several factors make the
hemodialysis (HD) population well suited to study the
relationship between PPI use and serum Mg concentra-
tion. First, HD patients have little or no urine output,
which reduces potential confounding related to renal
Mg loss. Furthermore, HD patients are typically dialyzed
against an ionized Mg concentration of 0.5 mmol/L or
less in the dialysate (corresponding to a total Mg con-
centration of approximately 0.7 mmol/L or less), such
that the dialysate Mg concentration would be insuffi-
cient to raise serum Mg in most instances.
We therefore hypothesized that mean serum Mg levels
among HD patients using PPIs would be lower than levels
among HD patients not on PPIs, and that increased ‘time
on PPI’ would be associated with lower serum Mg levels.
Methods
Patient population and study measurements
This was a cross-sectional study of 155 prevalent HD
patients at the Jewish General Hospital, a tertiary care aca-
demic hospital in Montreal, Quebec, Canada. All HD
patients in our program in February of 2011 were consid-
ered for inclusion in the study. Standard HD therapy con-
sisted of 4-hour treatments 3 times weekly using a high
flux dialyzer. Patients were excluded from the study if they
were receiving dialysis for acute kidney injury (within
3 months), if they were hospitalized at any time over the
3-month period during which the blood tests were drawn,
or if they had a history of chronic diarrhea, or an ileos-
tomy or colostomy. None of the patients were receiving
Mg-based phosphate binders or other Mg-based medica-
tions. Serum Mg concentration for each patient was deter-
mined based on the mean of 3 consecutive serum Mg
levels drawn at 6 week intervals as part of routine dialysis
blood testing. Data on PPI use was extracted from the dia-
lysis pharmacy database, and time on PPI at the time of
Mg measurement was also recorded.
The relationship between PPI use and serum Mg was
determined in unadjusted analyses, as well as after
adjustment for age, gender, race, cause of ESRD, dia-
betes, time on HD and dialysate Mg concentration. The
primary endpoint was the difference in the mean Mg
concentration in the presence or absence of PPI use.
Secondary endpoints included the proportion of HD pa-
tients with Mg levels below various cutoffs in the pres-
ence or absence of PPI use, and the relationship between
‘time on PPI’ and serum Mg concentration. Approval
was obtained from the Research Ethics Board at the
Jewish General Hospital prior to study initiation. No
written informed consent was obtained based on the
study’s retrospective nature.
Statistical analysis
Continuous data are presented as mean +/− standard de-
viation, or median and interquartile range as appropriate.
Continuous variables were compared using the Student’s
t-test for normally distributed data or the Mann–Whitney
test for non-normally distributed data, and using the chi-
square test for categorical variables. A multivariate linear
regression model was used to determine the independent
effect of PPI use on Mg levels after adjusting for age, gen-
der, race, diabetic status, cause of ESRD, time on HD and
dialysate Mg. Among PPI users, a multivariate linear re-
gression model was used to determine whether time on
PPI was predictive of serum Mg level. Statistical signifi-
cance was defined as a p value of <0.05. All statistical ana-
lyses were performed using SAS (version 9.3).
Results
A total of 180 patients were screened for inclusion, with
25 excluded due to either initiation of dialysis for acute
kidney injury, hospitalization during the time of data col-
lection or presence of chronic increased GI losses. Among
155 HD patients included in the study, mean age was
70 years, with a female and Caucasian predominance
(Table 1). Fifty five percent of patients were on PPIs at the






Age (mean, years) 72 ± 12 67 ± 17 0.05
Gender (% male) 33 % 30 % 0.78
Race (%) 0.09
Caucasian 74 % 64 %
Black 16 % 15 %
Asian 9 % 17 %
Other 0 % 4 %
Cause of ESRD 0.12
Hypertension 27 % 25 %
Diabetes 50 % 36 %
Glomerulonephritis 10 % 16 %
Polycystic kidney
disease
0 % 4 %
Other 13 % 18 %




0.5 mmol/L 58 % 67 %
0.375 mmol/L 42 % 33 %
Time on HD
(in months [IQR])
36 (20–63) 26 (16–43) 0.02
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time of the Mg measurements, and median time on the
PPI was 15 months (interquartile range 4–25 months).
The majority of patients (62 %) used a dialysate Mg of
0.5 mmol/L, and the remainder (38 %) used a dialysate
Mg of 0.375 mmol/L.
Serum Mg levels were significantly lower among PPI
users vs. non-users (0.93 vs. 1.02 mmol/L, p < 0.0001)
(Fig. 1). This finding persisted even after stratifying for
dialysate Mg concentration. More PPI users vs. non-
users had serum Mg levels < 1 mmol/L (79 % vs. 43 %,
p = 0.0003), and serum Mg levels < 0.8 mmol/L (16 %
vs. 4 %, p = 0.02) (Table 2). On multivariate analysis,
after adjustment for age, gender, race, cause of ESRD,
diabetes, time on HD and dialysate Mg concentration,
PPI use remained an independent predictor of lower
serum Mg (p = 0.0001). Among PPI users, there was a
trend toward increased time on PPI being associated
with lower serum Mg levels, but this did not reach stat-
istical significance (p = 0.067).
Discussion
In this cross-sectional study of prevalent HD patients,
we found that serum Mg levels among PPI users were
significantly lower than Mg levels of those who were not
on PPIs, even after adjustment for relevant covariates.
These results suggest that the effect of PPI use on GI
loss of Mg is likely present in a substantial proportion of
patients, and may therefore be an under-recognized en-
tity that only comes to clinical attention when the hypo-
magnesemia is severe enough to cause symptoms.
Since the emergence of numerous case reports of PPI-
induced hypomagnesemia over the last decade, increasing
attention has been paid to this issue. Several observational
studies have been published recently, with a majority
reporting on the relationship between PPIs and Mg levels
in hospitalized patients [7–9, 11, 13], and a few others
studying this association in various outpatient settings
[10, 12, 14]. Among the studies in hospitalized patients,
all but one [11] showed a significant relationship
between PPI use and lower serum Mg levels, and two
of the five studies in hospitalized patients showed that
hypomagnesemia was most pronounced in patients
concurrently on PPIs and diuretics [7, 9]. The observa-
tional studies that focused on non-hospitalized patients
included one in a large cohort of stable outpatients that
showed that PPI use in the 4 months prior to Mg meas-
urement was independently associated with hypomag-
nesemia [14]. In contrast, another outpatient study
performed in renal transplant recipients showed no rela-
tionship between PPIs and Mg levels [12]. However, the
latter study also failed to demonstrate any association be-
tween Mg levels and either diabetes or diuretics, both well
established etiologies of hypomagnesemia. One of the
most recent studies looked at 62 male HD outpatients
from a single center and showed a significant relationship
between PPI use and serum Mg levels [10]. Our study
adds to this literature by validating this association in a
larger and more diverse cohort of HD patients.
The basis for the Mg lowering effect of PPIs has yet to
be fully elucidated, but among over forty reported cases
of PPI-induced hypomagnesemia, the consistent finding
of low urinary Mg levels strongly suggests that Mg de-
pletion occurs in the GI tract. While passive absorption
accounts for most of GI Mg uptake, carrier-mediated
pathways involving TRPM-6 and TRPM-7 are also
known to be critical to GI Mg homeostasis [15]. While it
has been suggested that the major mechanism by which
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Fig. 1 Histogram of serum magnesium levels among PPI users vs. non-users
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inhibition [16], there is also some evidence that interfer-
ence with the passive absorption mechanism may underlie
this phenomenon [17, 18]. Another unexplained observa-
tion is the discrepancy between the ubiquity of PPI use and
the rarity of the associated hypomagnesemia. Although this
may indicate an idiosyncratic side-effect of PPI use, our re-
sults and those of others show that absolute Mg levels re-
main lower in PPI users, suggesting that PPIs have a
consistent Mg-depleting effect in most patients. In support
of this is the finding that PPI users predictably demonstrate
enhanced renal Mg absorption [19], indicating chronic
subclinical depletion in this population.
While the differences in Mg levels between PPI users
and non-users in our study were highly statistically signifi-
cant, it remains to be determined whether the lower
serum Mg levels among PPI users are clinically significant.
Potential adverse outcomes that have been associated with
lower Mg levels in dialysis patients include hyperparathyr-
oidism, vascular calcification and mortality. For example,
Mg levels in dialysis patients have been shown in observa-
tional studies to be inversely proportional to parathyroid
hormone levels in both HD [20–22] and peritoneal dialy-
sis populations [23, 24]. In addition, Mg is known to
inhibit calcification in vascular smooth muscle cells in
vitro [25, 26], and there have been several observational
studies demonstrating an association between lower
serum Mg levels and vascular calcification [27–29] or mi-
tral annular calcification [30]. Furthermore, a recent small
randomized pilot study showed that supplementation with
Mg carbonate for 1 year in HD patients led to improved
calcification scores in some patients [31]. In this latter
trial, the difference in Mg levels between the groups was
small but significant (1.16 vs. 1.04 mmol/L). Finally, there
are limited data suggesting an association between lower
Mg levels and increased mortality among HD patients.
This was first illustrated in an observational study of 515
HD patients, in whom baseline serum Mg concentration
(measured over a 4 month period) predicted mortality
[32]. Specifically, after a mean of 51 months of follow-up,
those with serum Mg <1.14 mmol/L had a higher mortal-
ity relative to those with Mg levels ≥ 1.14 mmol/L. More
recently, in a Japanese registry-based cohort study of
142,555 HD patients by Sakaguchi et al., Mg concentra-
tions in the 3 lowest sextiles (corresponding to Mg levels
< 1.10 mmol/L) were associated with higher all-cause
mortality, including increased cardiovascular mortality
and non-cardiovascular mortality [33]. While the data to
date are almost all observational, they raise the possibility
that subtle differences in Mg levels even within the normal
range among dialysis patients can have an impact on clin-
ically meaningful outcomes.
While the major strength of this study is the use of a
stable, outpatient population with minimal residual renal
function to confound the site of Mg loss, the study has
some limitations. First, it is cross-sectional in nature, and
therefore does not allow for description of the evolution
of Mg levels among PPI users. Second, we did not meas-
ure dietary Mg intake, markers of nutritional status, Kt/V
or renal Mg loss. However, for the latter variable, given
that the median time on HD was 32 months, the extent of
renal Mg loss would be minimal [34] and would have been
unlikely to confound the results. Third, we studied serum
Mg levels, but did not specifically look at the ionized Mg
fraction. Fourth, while we did not document adherence,
PPI use was determined from our dialysis pharmacy rec-
ord, which was updated every 2–3 months based on con-
tact with the patients’ outpatient pharmacies. Lastly, the
study may have been underpowered to detect other
significant associations, such as the impact of duration of
PPI use on Mg levels, which trended toward but did not
reach significance in our study.
Conclusion
In conclusion, in this single-center study using a cross-
sectional design, we have shown that PPI use is associated
with significantly lower levels of serum Mg in stable HD
patients, suggesting that the effect of PPIs on Mg homeo-
stasis is much more prevalent than originally thought.
While we did not study the association between lower Mg
levels and adverse outcomes, there is a growing literature
among dialysis patients on the potential link between lower
Mg levels and the risk of calcification, hyperparathyroidism
and mortality. Further research is required to determine
whether the magnitude of change in Mg levels among PPI
users on HD is associated with adverse outcomes.
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